Tuesday, 13 September 2022

Lupin Receives Health Canada Approval for Rymti (biosimilar Etanercept)

Lupin Receives Health Canada Approval for Rymti (biosimilar Etanercept)
Lupin Receives Health Canada Approval for Rymti

Lupin Limited announced that Health Canada has approved Rymti, its biosimilar to Enbrel (etanercept), for use in Canada.

Rymti® is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis.

Pradip Mahajan Tue, 09/13/2022 - 14:54

source https://www.pharmatutor.org/pharma-news/2022/lupin-receives-health-canada-approval-for-rymti

No comments:

Post a Comment

Pharma openings

  Opportunity for M.Pharm, Msc or PhD as Scientist at PGIMER M.Pharmacy or M.Sc 6 Year of Research Experience or PhD with 3 year of Experien...